This makes it the second Indian firm to study the broad-spectrum antiviral drug favipiravir’s use in treating covid-19 Strides Pharma Science Ltd will soon start clinical trials on potential coronavirus drug favipiravir, it said on Thursday.
This makes it the second Indian company to study the broad-spectrum antiviral drug’s use in treating the fatal respiratory disease after Glenmark Pharmaceuticals Ltd.
The development comes even as world over multiple existing drugs are being looked at for treatment of the novel coronavirus infection, including the anti-malarial hydroxychloroquine (HCQ), the anti-cancer combination of lopinavir and ritonavir, and Gilead’s patented drug remdesivir, which had earlier failed trials to cure ebola. “We have